

High-Impact Clinical Trials

Hall B1

Moderators:

Orlando M. Gutierrez, MD and Monnie Wasse, MD, FASN

-
- 10:00 a.m. Introduction
- 10:35 a.m. **Acute Kidney Injury from Off-Pump or On-Pump Coronary Bypass Grafting and Kidney Function One Year Later** — *Amit X. Garg¹, Philip J. Devereaux², Salim Yusuf², Meaghan S. Cuerden¹, Chirag R. Parikh³, Steven G. Coca³, Michael Walsh², Richard J. Cook³, Richard P. Whitlock², Richard J. Novick³, Yongning Ou², Xiangbin Pan³, Sirish Parvathaneni³, Andre Lamy². ¹London Kidney Clinical Research Unit, London, Canada; ²Population Health Research Institute, Hamilton, Canada; ³On Behalf of the CORONARY Investigators.*
- 10:50 a.m. **The Effect of Bardoxolone Methyl in Patients with Type 2 Diabetes Mellitus and Stage 4 Chronic Kidney Disease** — *Glenn M. Chertow¹, Tadao Akizawa², Paul Audhya³, George L. Bakris⁴, Melanie Chin³, Heidi Christ-schmidt⁵, Angie Goldsberry³, Hiddo Jan Lambers Heerspink⁶, Mark T. Houser⁷, Melissa Krauth³, John J. McMurray⁸, Colin John Meyer³, Hans-Henrik Parving⁹, Giuseppe Remuzzi¹⁰, Robert D. Toto¹¹, Nosratola D. Vaziri¹², Christoph Wanner¹³, Janet Wittes⁵, Danielle Wroldstad⁶, Dick de Zeeuw⁶. ¹Stanford U.; ²Showa U.; ³Reata; ⁴U. Chicago; ⁵Statistics Collaborative; ⁶U. Groningen; ⁷AbbVie; ⁸U. Glasgow; ⁹U. Copenhagen; ¹⁰IRCCS - Mario Negri; ¹¹U. TX SW Med Ctr; ¹²U. CA; ¹³U. Würzburg.*
- 11:05 a.m. **Combined Angiotensin Inhibition for Treatment of Diabetic Nephropathy: VA Nephron D** — *Linda F. Fried¹, Nicholas Emanuele², Jane Hongyuan Zhang³, Mary Brophy⁴, Todd Conner⁵, William Duckworth⁶, David J. Leehey⁷, Peter A. McCullough⁷, Theresa Z. O'connor³, Paul M. Palevsky¹, Robert F. Reilly⁸, Stephen L. Seliger⁹, Stuart Warren⁵, Suzanne Watnick¹⁰, Peter Peduzzi³; Peter Guarino³. ¹VA Pittsburgh HCS, Pittsburgh, PA; ²Hines VA, Hines, IL; ³Cooperative Studies Program Coordinating Center, VA Connecticut HCS, West Haven, CT; ⁴VA Boston HCS, Boston, MA; ⁵VA Cooperative Studies Program Research Pharmacy, Albuquerque, NM; ⁶Carl T. Hayden VA Medical Center, Phoenix, AZ; ⁷St. John Providence Health System, Novi, MI; ⁸VA North Texas HCS, Dallas, TX; ⁹VA Maryland HCS, Baltimore, MD; ¹⁰Portland VA Medical System, Portland, OR.*
- 11:25 a.m. **Hypertension in Hemodialysis Patients Treated with Atenolol or Lisinopril (HDPAL): A Randomized Controlled Trial** — *Rajiv Agarwal^{1,2}, Arjun D. Sinha^{1,2}, Maria K Pappas^{1,2}, Terri N Abraham^{1,2}, Getachew G. Tegegne^{1,2}. ¹Medicine, Indiana Univ, Indianapolis, IN; ²Medicine, VAMC, Indianapolis, IN.*
- 11:40 a.m. **Safety and Efficacy of ZS-9, a Novel Selective Cation Trap, for Treatment of Hyperkalemia in CKD Patients** — *Stephen R. Ash¹, Bhupinder Singh², Phillip T. Lavin³, Fiona Stavros⁴, Henrik S. Rasmussen⁴. ¹Indiana Univ, Lafayette, IN; ²Southwest Clinical Research Institute, Tempe, AZ; ³Boston Biostatistics Research Foundation, Framingham, MA; ⁴ZS Pharma Inc., Fort Worth, TX.*
- 11:55 a.m. **Treatment of Lupus Nephritis with Abatacept Plus Low-Dose Pulse Cyclophosphamide: The Results of the ACCESS Trial** — *Brad H. Rovin¹, The Access Trial Investigators². ¹Internal Medicine, Ohio State Univ Wexner Medical Center, Columbus, Ohio; ²The Immune Tolerance Network.*
- 12:10 p.m. **APOL1 Risk Variants, Race, and Progression of Chronic Kidney Disease** — *Afshin Parsa¹, Wen Hong Linda Kao², The AASK and CRIC Collaborative Research Groups^{1,2}. ¹Nephrology, Univ of Maryland School of Medicine; ²Epidemiology, Johns Hopkins Bloomberg School of Public Health.*
- 12:25 p.m. Wrap-Up

Late-Breaking Clinical Trial Posters

Halls B3/B4

- SA-PO1076 **A Randomized Clinical Trial to Evaluate the Efficacy of Cinacalcet to Correct Hypercalcemia in Renal Transplant Recipients with Autonomous Hyperparathyroidism** — *Pieter Evenepoel¹, Kerry Cooper², Hallvard Holdaas³, Piergiorgio Messa⁴, Georges J. Mourad⁵, Klaus Olgaard⁶, Boleslaw Rutkowski⁷, Heidi M. Schaefer⁸, Hongjie Deng², Jose-Vicente Torregrosa⁹, Rudolf P. Wuthrich¹⁰, Susan V. Yue²*. ¹U Ziekenhuizen, Belgium; ²Amgen, USA; ³Oslo U Hospital, Norway; ⁴Fondazione Ca' Granda IRCCS Policlinico, Italy; ⁵U of Montpellier Hospital Lapeyronie, France; ⁶U of Copenhagen, Denmark; ⁷Medical U of Gdansk, Poland; ⁸Vanderbilt U Medical Center; ⁹U of Barcelona, Spain; ¹⁰U Hospital Zurich, Switzerland.
- SA-PO1077 **18 Month Results from a Randomized Trial of Mycophenolate Mofetil versus Cyclophosphamide for Remission Induction of Severe ANCA-Associated Vasculitis: MYCYC** — *Rachel B. Jones¹, Lorraine Harper², Michael Walsh³, David R.W. Jayne¹*. ¹Addenbrooke's Hospital; ²Univ of Birmingham; ³McMaster Univ.
- SA-PO1078 **Continuous, Maintenance Iron Therapy Using Soluble Ferric Pyrophosphate Citrate Chelate (SFP, Triferic™) Infusion via Hemodialysate in CKD-HD: Phase III CRUISE Studies** — *Steven Fishbane³, Ajay K. Singh², Raymond D. Pratt¹, Vivian H. Lin¹, Carrie D. Guss¹, Ajay Gupta¹*. ¹R&D, Rockwell Medical, Wixom, MI; ²Nephrology, Brigham and Women's Hospital, Boston, MA; ³Nephrology, North Shore - Long Island Jewish Health System, Inc., Manhasset, NY.
- SA-PO1079 **FIND-CKD: A 56-Week Randomized Trial of Intravenous Ferric Carboxymaltose versus Oral Iron in Anemic Patients with Chronic Kidney Disease and Iron Deficiency** — *Iain C. Macdougall¹, Andreas H. Bock², Fernando Carrera², Kai-Uwe Eckardt², Carlo A. Gaillard², David B. Van Wyck², Bernard Roubert³, Jacqueline G. Nolen³, Simon D. Roger²*. ¹King's College Hospital, London, United Kingdom; ²On behalf of the FIND-CKD Study Investigators; ³Vifor Pharma, Switzerland.
- SA-PO1080 **Increased Duration and Dose of Prednisolone (PSL) Treatment Does Not Reduce Relapses in Childhood Nephrotic Syndrome** — *Norishige Yoshikawa¹, Koichi Nakanishi¹, Mari Saito OBA², Mayumi Sako³, Yasuo Ohashi⁴, Kazumoto Iijima⁵*. ¹Wakayama Medical Univ, Japan; ²Yokohama City Univ; ³National Center for Child Health and Development; ⁴Univ. of Tokyo; ⁵Kobe Univ.
- SA-PO1081 **The Antialbuminuric Effects of an Aldosterone Blocker in Hypertensive Patients with Albuminuria: A Double-Blinded, Randomized, Placebo-Controlled (EVALUATE) Trial** — *Toshiro Fujita¹, Shunya Uchida², George Seki³, Shinya Kaname⁴*. ¹Dept of Epigenetics, RCAST, Univ of Tokyo, Tokyo, Japan; ²Dept of Nephrology, Teikyo Univ, Tokyo, Japan; ³Dept of Nephrology & Endocrinology, Univ of Tokyo, Tokyo, Japan; ⁴Dept of Nephrology, Kyorin Univ, Tokyo, Japan.
- SA-PO1082 **The DIVINE Trial: Dialysis Infection and Vitamin D in New England** — *Ishir Bhan, Dorothy A. Dobens, Caitlin A. Trottier, Julia Beth Wenger, Hector Tamez, Joseph James Deferio, Kathryn J. Lucchesi, Ravi I. Thadhani*. Div of Nephrology, Massachusetts General Hospital, Boston, MA.
- SA-PO1083 **Prospective Randomized Controlled Trial of Individualized Dialysate Cooling to Provide Brain and Cardiac Protection in Haemodialysis Patients** — *Chris W. McIntyre, Mohamed Tarek Eldehni, Aghogho Odudu*. Div of Medical Sciences and Graduate Entry Medicine, School of Medicine, Univ of Nottingham, Derby, United Kingdom.
- SA-PO1084 **A Randomized Controlled Multicenter Trial of a Heparin-Grafted Polyacrylonitrile Membrane for No-Heparin Hemodialysis versus Standard-of-Care: Results of the HepZero Study** — *Maurice Laville¹, Marc Dorva², Joan Fort³, Renaud Fay⁴, Frederique Moureaux⁴, Nathalie Loughraieb⁴, Patrick Rossignol⁵*. ¹Nephrology Dept, Lyon-Sud Hospital Centre, Lyon Univ, INSERM U1060 & AURAL, Lyon, France; ²Dr-Georges-L.-Dumont Univ Hospital Centre, Moncton, Nouveau-Brunswick, Canada; ³Nephrology Dept, Univ Hospital Vall d'Hebron, Autonomous Univ of Barcelona, Spain; ⁴Gambro-Hospital, Meyzieu, France; ⁵INSERM CIC 9501 & U1116, Nancy-Univ Hospital, Lorraine Univ & ALTIR, Nancy, France.
- SA-PO1085 **A Two-Part Trial of Patiromer for the Treatment of Hyperkalemia in Chronic Kidney Disease Subjects on Renin Angiotensin Aldosterone System Inhibition** — *Matthew R. Weir¹, George L. Bakris², Martha Mayo³, Yuri Stasis³, Heidi Christ-schmidt⁴, Janet Wittes⁴, Lance Berman³*. ¹Univ of Maryland; ²Univ of Chicago Medicine; ³Relypsa; ⁴Statistics Collaborative.

- SA-PO1086 **Effects of Atorvastatin on Renal Function in Patients with Dyslipidemia and Chronic Kidney Disease: ASsessment of Clinical Usefulness in CKD Patients with Atorvastatin (ASUCA) Trial** — *Genjiro Kimura¹, Kenji Ueshima², Masato Kasahara², Sachiko Tanaka², Shinji Yasuno², Akira Fujimoto², Tosiya Sato³, Shinji Kosugi⁴, Kazuwa Nakao⁵*.
¹Asahi Rosai Hospital, Owariasahi, Japan; ²Dept of EBM Research, Institute of Advancement of Clinical and Translational Science, Kyoto Univ Hospital, Kyoto, Japan; ³Dept of Biostatistics, Kyoto Univ School of Public Health, Kyoto, Japan; ⁴Dept of Medical Ethics/Medical Genetics, Kyoto Univ School of Public Health, Kyoto, Japan; ⁵Medical Innovation Center, Kyoto Univ Graduate School of Medicine, Kyoto, Japan.
- SA-PO1087 **A Randomized, Placebo-Controlled Trial of Oxpentifylline on Erythropoiesis Stimulating Agent Resistance in Anemic Patients with Chronic Kidney Disease: The HERO Trial** — *Sunil V. Badve^{1,2}*. ¹Nephrology, Princess Alexandra Hospital, Brisbane, QLD, Australia; ²The Australasian Kidney Trials Network, Brisbane, QLD, Australia.
- SA-PO1088 **Abstract Withdrawn.**
- SA-PO1089 **Risk and Severity of Hyperkalemia with Combined Angiotensin Antagonism in Diabetic Nephropathy – The VA-NEPHRON-D Study** — *Stephen L. Seliger¹, Jane Hongyuan Zhang⁴, Nicholas Emanuele³, Paul M. Palevsky², Linda F. Fried⁵*. ¹Medicine, Baltimore VA, Baltimore, MD; ²Medicine, Pittsburgh VA, Pittsburgh, MD; ³Medicine, Hines VA, Hines, IL; ⁴Coordinating Ctr, VA Co-Operative Studies, West Haven, CT.
- SA-PO1090 **A Comparison of Short-Term Exposure of Once-Daily Extended Release Tacrolimus (Advagraf[®]) and Twice-Daily Tacrolimus (Prograf[®]) on 24 Hour Renal Hemodynamics and Function in Healthy Volunteers** — *David Cherney, Jeffrey S. Zaltzman*. Univ of Toronto.
- SA-PO1091 **Changes in Cardiac Structure and Function after Revascularization versus Medical Therapy for Renal Artery Stenosis: The ASTRAL Heart Echocardiography Sub-Study** — *Darren Green¹, Natalie Ives², Kelly Handley², Philip A. Kalra¹*. ¹Salford Royal Hospital, United Kingdom; ²Univ of Birmingham, United Kingdom.
- SA-PO1092 **Four-Week Safety, Efficacy and Pharmacodynamic Study of Hypoxia-Inducible Factor (HIF)-Prolyl Hydroxylase Inhibitor GSK1278863 in Anemic Hemodialysis Subjects Switching from Recombinant Human Erythropoietin** — *Amy M. Meadowcroft, Louis Holdstock, Rayma Maier, Delyth Jones, Brendan Johnson, Alexander Ralph Cobitz, John J. Lepore*. GlaxoSmithKline, Research Triangle Park, North Carolina.
- SA-PO1093 **Randomized Controlled Trial on the Effects of a Six-Month Intradialytic Physical ACTivity Program and Adequate NUTritional Support on Protein-Energy Wasting, Physical Functioning and Quality of Life in Chronic Hemodialysis Patients ACTINUT** — *Dan Hristea, Anne Paris, Justine Magnard, Thibault Deschamps²*. ¹Dialysis, ECHO, Nantes, France; ²STAPS, Nantes, France.
- SA-PO1094 **The Pharmacokinetics of Laquinimod and Mycophenolate Mofetil during Treatment of Active Lupus Nephritis** — *David R.W. Jayne¹, Gerald B. Appel², Daniel Tak Mao Chan³, Dorit Mimrod⁴, Ofer Spiegelstein⁴, Hadas Barkay⁴, Roberta Weiss⁵, David Wofsy⁶*. ¹Addenbrooke's Hospital, London, United Kingdom; ²Columbia Univ, New York, New York; ³Univ of Hong Kong, Hong Kong; ⁴Teva Pharmaceuticals, Netanya, Israel; ⁵Teva Pharmaceuticals, Frazer, PA; ⁶Univ of California at San Francisco, San Francisco, CA.
- SA-PO1095 **Universal Prophylaxis for Cytomegalovirus in Pediatric Kidney Transplantation in Developing Country: Medellin, Colombia** — *Liliana Rubio, Jorge Henao, Joaquin Rodelo Ceballos*. Pediatric Nephrology, Hospital Universitario San Vicente Fundacion, Medellin, Antioquia, Colombia.
- SA-PO1096 **Acute Kidney Injury (AKI) Associated with Combined Angiotensin Antagonism in Patients with Diabetic Nephropathy – A Secondary Analysis of the VA NEPHRON-D Study** — *Paul M. Palevsky¹, Jane Hongyuan Zhang², Stephen L. Seliger³, Nicholas Emanuele⁴, Linda F. Fried⁵*. ¹VA Pittsburgh HCS, Pittsburgh, PA; ²CSP Coordinating Center, VA Connecticut HCS, West Haven, CT; ³VA Maryland HCS, Baltimore, MD; ⁴Hines VAMC, Hines, IL.